Alfacalcidol

• CAT Number: A000897
• CAS Number: 41294-56-8
• Molecular Formula: C27H44O2
• Molecular Weight: 400.64
• Purity: ≥95%
• Synonyms: (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
• InChI: InChI=1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1
• InChIKey: OFHCOWSQAMBJIW-AVJTYSNKSA-N
• SMILES: CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C

Alfacalcidol (Cat No.: A000897) is a vitamin D analog used to treat conditions related to calcium and phosphate imbalance, such as osteoporosis, renal osteodystrophy, and hypoparathyroidism. It is rapidly converted in the liver to calcitriol, the active form of vitamin D, bypassing the need for kidney hydroxylation. Alfacalcidol enhances intestinal calcium absorption and regulates bone mineralization and parathyroid hormone levels. Administered orally or intravenously, it is generally well-tolerated. Side effects may include hypercalcemia, headache, nausea, and fatigue, especially with prolonged or high-dose use.

Reference

[1]. Galeşanu C, et al. [Postmenopausal osteoporosis. Digital Rx radiogrammetry in the diagnosis and follow-up of treatment with alfacalcidol]. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):833-41.
[Content Brief]

[2]. Nuijten M, et al. Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK. Clin Drug Investig. 2010;30(8):545-57.
[Content Brief]

[3]. Shiraishi A, et al. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int. 1999 Oct;65(4):311-6.
[Content Brief]

[4]. Nagaoka H, et al. Alfacalcidol enhances collagen quality in ovariectomized rat bones. J Orthop Res. 2014 Aug;32(8):1030-6.
[Content Brief]